Extract
One-third to one-quarter of the world's population is estimated to have latent tuberculosis infection (LTBI) [1]. These infected persons are at risk for developing active disease with a lifetime risk of reactivation estimated to be 5–10% [2]. Prevention of reactivation of LTBI in population groups with higher risk of progression to active disease than the general population, is critical to end the global TB epidemic [3].
Abstract
Treatment of latent tuberculosis infection in children with a 3-month daily rifampicin and isoniazid regimen is safe with better compliance, adherence and completion rate than a 6- or 9-month isoniazid monotherapy http://ow.ly/x28Z30jDfCE
Footnotes
This is one of a selection of articles published open access, as part of an initiative agreed between the European Respiratory Society and the World Health Organization.
Conflict of interest: None declared.
- Received February 23, 2018.
- Accepted April 13, 2018.
- Copyright ©ERS 2018
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.